News, Scientific publications and Events

Corporate Press Release: Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis

Corporate Press Release: Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis. The agreement will see the global launch of Noventure’s novel nasal mucoprotection product.

Uro-ginecology News UTIPRO® PLUS

Utipro® Plus Launched In France

We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.

Uro-ginecology News UTIPRO® PLUS

Utipro® Plus Launched In Israel

We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections. Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017. Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)